Vitamin E

Vitamin E's mechanism centers on its role as the primary chain-breaking lipid-phase antioxidant — intercepting lipid peroxyl radicals to halt the chain reaction of lipid peroxidation — plus emerging non-antioxidant signaling functions including modulation of protein kinase C, phospholipase A2, vascular smooth muscle cell proliferation, and gene expression. Tocotrienols have partially distinct mechanisms including HMG-CoA reductase regulation. The molecular biology requires tracking lipid peroxidation chemistry, α-TTP-mediated selective retention, and co-nutrient recycling.

Lipid peroxidation chain reaction. Polyunsaturated fatty acids (PUFAs) in membrane phospholipids and lipoproteins are vulnerable to peroxidation when radical species abstract a bis-allylic hydrogen. The initial reaction: R• + LH → RH + L• (carbon-centered lipid radical). The carbon radical reacts with molecular oxygen: L• + O2 → LOO• (lipid peroxyl radical). The peroxyl radical abstracts another bis-allylic hydrogen from an adjacent PUFA: LOO• + LH → LOOH + L• — propagating the chain and destroying lipid structural integrity. Unchecked, each initiating radical can propagate through hundreds of PUFA molecules, destroying membrane function and generating toxic end products (4-hydroxynonenal, malondialdehyde, acrolein, F2-isoprostanes). Vitamin E intercepts the chain at the peroxyl radical step.

α-Tocopherol chain-breaking reaction. α-tocopherol (α-TOH) donates its phenolic 6-O-H hydrogen to the peroxyl radical: LOO• + α-TOH → LOOH + α-TO•. The resulting α-tocopheroxyl radical (α-TO•) is kinetically stabilized by the chromanol ring system and the 5-, 7-, 8-methyl substituents, such that it does not propagate further lipid oxidation (or does so only at very slow rates). The peroxyl radical is now converted to a lipid hydroperoxide (LOOH) — a less reactive species that can be reduced to a non-radical lipid alcohol (LOH) by glutathione peroxidase 4 (GPX4), using glutathione and selenium. This selenium-dependent GPX4 step is why vitamin E and selenium have synergistic biology — they operate at sequential steps of the same defensive pathway.

α-Tocopheroxyl radical recycling. Unlike a purely sacrificial antioxidant, the α-tocopheroxyl radical can be reduced back to α-tocopherol by several reducing systems: (1) vitamin C (ascorbate) at the aqueous-lipid interface donates a hydrogen: ASCH- + α-TO• → α-TOH + ASC•-, generating the ascorbyl radical (which is then reduced back to ascorbate by NADH-dependent reductases or glutathione). (2) Ubiquinol (CoQ10) within the lipid bilayer is the membrane-phase recycler: CoQH2 + α-TO• → CoQH• + α-TOH, with CoQH• reduced back to CoQH2 by electron transport chain flux. (3) Glutathione (GSH) and thiol-containing enzymes also contribute. This cycling is why functional vitamin E status depends on adequate vitamin C, CoQ10, selenium (for GPX4), and reducing power (NADPH from the pentose phosphate pathway).

γ-Tocopherol chemistry. γ-tocopherol has an unmethylated 5-position on the chromanol ring, exposing a nucleophilic carbon adjacent to the phenolic OH. This allows γ-tocopherol to trap nitrogen dioxide and peroxynitrite (reactive nitrogen species, RNS) through direct 5-nitration to form 5-nitro-γ-tocopherol — a reaction α-tocopherol cannot undergo because its 5-position is fully methylated. This chemistry makes γ-tocopherol a specialist for RNS detoxification, particularly relevant in inflammatory contexts with iNOS induction. High-dose α-tocopherol supplementation suppresses serum γ-tocopherol levels (via CYP4F2 induction and displacement), which is one reason mixed-tocopherol supplements or dietary sources of γ-tocopherol (walnuts, pecans, soybean oil) may have value that isolated α-tocopherol cannot replicate.

α-TTP selective retention mechanism. α-Tocopherol transfer protein (α-TTP, TTPA gene) is a 30 kDa cytosolic hepatic protein that binds α-tocopherol with high affinity (Kd ~10 nM) and lower affinity for other isoforms (β ~30%, γ ~10%, δ <3%, tocotrienols <10%). α-TTP loads α-tocopherol onto nascent VLDL particles via interaction with liver X receptor and other nuclear receptors regulating lipoprotein assembly. Molecular characterization by Arita 1995 (PMID 9013565) and crystal structure by Min 2003 (PMID 14607114) established the binding pocket geometry that discriminates between isoforms. Without functional α-TTP, dietary α-tocopherol is rapidly degraded and tissue vitamin E falls; AVEDreflects this biology clinically.

CYP4F2-mediated catabolism. Non-α-tocopherol isoforms and excess α-tocopherol are cleared by hepatic ω-hydroxylation by CYP4F2, producing 13'-hydroxy-tocopherol intermediates that undergo further β-oxidation to yield carboxyethyl hydroxychromans (CEHCs) excreted in urine. The α-CEHC urinary output is a biomarker of α-tocopherol intake; γ-CEHC similarly reflects γ-tocopherol intake. CYP4F2 polymorphism rs2108622 (V433M) substantially affects vitamin E half-life and steady-state concentrations; carriers retain α-tocopherol longer and may require lower supplement doses.

Non-antioxidant signaling. α-Tocopherol directly inhibits protein kinase C α (PKCα) through specific binding and competitive displacement of diacylglycerol, which has downstream effects on vascular smooth muscle cell proliferation, platelet aggregation, and endothelial adhesion molecule expression (Azzi 2004 reviews, and others). α-Tocopherol also modulates phospholipase A2 activity, affecting eicosanoid production; directly regulates transcription of CD36, α-TTP, COX-2, and several other genes; and affects membrane fluidity through specific lipid raft interactions. The distinction between "vitamin E as antioxidant" vs. "vitamin E as specific ligand/regulator" is blurring; both mechanisms co-exist in vivo.

Tocotrienol-specific mechanisms. δ- and γ-tocotrienols have been shown to post-translationally regulate HMG-CoA reductase — they trigger ER-associated degradation of the reductase through Insig-mediated proteolysis, similar to oxysterol-induced down-regulation. This provides a mechanism for the modest LDL-cholesterol-lowering effects observed in small tocotrienol trials (5-15% LDL reduction at 150-300 mg/day annatto-derived tocotrienols). Tocotrienols also have distinct interactions with membrane cholesterol and sphingolipids due to their unsaturated side chain, which may underlie differential effects on lipid rafts and downstream signaling. δ-tocotrienol has been studied for breast cancer cell biology in vitro and for bone formation, though human data remain limited.

Interaction with vitamin K cycle. High-dose α-tocopherol (above ~400 IU/day) competitively inhibits vitamin K-dependent γ-carboxylation of clotting factors II, VII, IX, X and of proteins C, S, Z — the same biology targeted by warfarin. Booth 2004demonstrated that α-tocopherol 1000 IU/day for 12 weeks in healthy older adults modestly reduced plasma phylloquinone and altered vitamin K-dependent carboxylation markers. The clinical consequence: high-dose α-tocopherol supplementation is contraindicated in patients on warfarin without close INR monitoring, and can increase bleeding risk when combined with antiplatelet drugs or anticoagulants. Vitamin K adequacy (adequate vitamin K2 status, or menaquinone from fermented foods) reduces this interaction.

Interaction with NADPH oxidase and inflammatory signaling. α-tocopherol inhibits NADPH oxidase assembly in phagocytic cells, reducing superoxide production. This is probably the mechanism for some of the immunomodulatory effects in elderly populations (Meydani 1997 JAMA) where supplementation improved T-cell mediated immunity markers. Tocotrienols similarly modulate NF-κB signaling and cytokine production.

Interaction with the γ-tocopherol-nitration pathway. In settings of chronic inflammation with high iNOS expression (atherosclerotic plaques, inflammatory bowel disease tissue), γ-tocopherol is preferentially consumed to form 5-nitro-γ-tocopherol, with ratios of γ-tocopherol/α-tocopherol declining as marker of oxidative/nitrosative stress. This has generated interest in γ-tocopherol-specific or mixed-tocopherol supplementation in inflammation-driven conditions, though outcome trials are limited.

Vitamin E is the collective name for eight naturally occurring fat-soluble molecules — four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ) — sharing a chromanol head group and a 16-carbon isoprenoid side chain. Tocopherols have a saturated side chain; tocotrienols have three trans double bonds in the same chain, giving them distinct membrane packing and lipid-raft interactions. All eight forms were historically considered "vitamin E" by their ability to rescue the original Evans 1922 rat fertility assay — adult female rats fed a strictly vitamin-E-free diet developed infertility that reversed on re-feeding with a factor extracted from wheat germ oil, later named α-tocopherol from Greek roots meaning "to bring forth offspring." Current nutritional science privileges α-tocopherol as the sole form meeting vitamin E requirements in humans, because the hepatic α-tocopherol transfer protein (α-TTP) selectively loads α-tocopherol into VLDL for export to peripheral tissues while preferentially degrading the other seven isomers through cytochrome P450-mediated ω-hydroxylation (CYP4F2 is the major enzyme). This discrimination, first characterized by the Arita group (Nature 1995; α-TTP crystal structure), is why α-tocopherol alone is used to define the RDA (15 mg/day for adults) and why isolated α-tocopherol supplementation suppresses serum γ-tocopherol levels — a potential issue given that γ-tocopherol has distinct antioxidant properties and can neutralize peroxynitrite in ways α-tocopherol cannot.

Structurally, α-tocopherol is 2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol — a chromanol head group fully methylated at positions 5, 7, and 8, with a 16-carbon phytyl-derived isoprenoid tail. The phenolic 6-OH is the business end of the antioxidant chemistry; when a lipid peroxyl radical (LOO•) abstracts the O-H hydrogen, it generates a lipid hydroperoxide (LOOH, less reactive and more easily cleared) and the relatively stable α-tocopheroxyl radical (α-TO•). The tocopheroxyl radical is then reduced back to α-tocopherol by vitamin C (ascorbate) at the aqueous-lipid interface, by ubiquinol (CoQ10), or by glutathione — and the regenerated α-tocopherol returns to the membrane to intercept another peroxyl radical. This is the "redox recycling" biology that makes vitamin E a chain-breaking antioxidant rather than a stoichiometric sacrifice — one α-tocopherol molecule can neutralize hundreds of peroxyl radicals over its functional lifetime given adequate reducing co-nutrients.

Natural α-tocopherol is the single RRR stereoisomer (the biologically active enantiomer, previously designated d-α-tocopherol). Synthetic α-tocopherol produced by chemical synthesis is all-rac-α-tocopherol (previously dl-α-tocopherol), a racemic mixture of all eight possible stereoisomers; only the RRR form is fully active, so synthetic is typically assigned 0.74× the biological activity of natural per unit mass by the Institute of Medicine's 2000 conversion. Esters (α-tocopheryl acetate, α-tocopheryl succinate, α-tocopheryl nicotinate) are prodrug forms that are hydrolyzed in the gut or tissue by esterases to free α-tocopherol; the ester forms are more chemically stable against oxidation during storage. Tocopheryl acetate is the most common supplement form. The unit convention is: 1 mg RRR-α-tocopherol = 1 α-tocopherol equivalent (α-TE) = 1.49 IU. Synthetic all-rac-α-tocopherol: 1 mg = 1 IU. So a 400 IU supplement of synthetic dl-α-tocopheryl acetate provides 400 mg of the racemic mixture and roughly 180 mg of bioactive RRR-equivalent.

Intestinal absorption of vitamin E requires dietary fat and bile acids; free vitamin E (and ester-hydrolyzed free forms) partitions into mixed micelles, enters enterocytes primarily via NPC1L1 (the same transporter ezetimibe inhibits) and passive diffusion, is packaged into chylomicrons with other fat-soluble vitamins and dietary triglycerides, and reaches the liver. Hepatocytes express α-TTP in the cytosol; α-TTP binds α-tocopherol with roughly 10- to 20-fold higher affinity than other isoforms and loads it into nascent VLDL for export to peripheral tissues. Non-α-tocopherol isoforms (γ, δ, β, tocotrienols) are preferentially directed to hepatic CYP4F2-mediated ω-hydroxylation, generating CEHCs (carboxyethyl hydroxychromans) and other polar metabolites that are urinary-excreted. The consequence: steady-state plasma α-tocopherol is typically 20-35 μmol/L, while γ-tocopherol is 2-5 μmol/L despite γ-tocopherol being a more abundant isoform in the US food supply due to soybean oil dominance.

Hepatic α-TTP function determines vitamin E sufficiency. Mutations in α-TTP (TTPA gene) cause ataxia with vitamin E deficiency (AVED Ouahchi Nature Genetics 1995), an autosomal recessive neurodegenerative disease with spinocerebellar phenotype resembling Friedreich ataxia. Without functional α-TTP, α-tocopherol cannot be retained after hepatic uptake, is rapidly degraded, and tissue vitamin E falls. Patients develop progressive ataxia, dysarthria, dysmetria, and areflexia — but the striking fact is that high-dose α-tocopherol supplementation (800-2000 mg/day) can reverse progression and stabilize or improve neurologic status, establishing both the essentiality of α-tocopherol and the tractability of isolated deficiency as a therapeutic target. Abetalipoproteinemia (MTP mutations) produces similar functional vitamin E deficiency through failure of chylomicron and VLDL assembly, and is similarly managed with mega-dose α-tocopherol supplementation.

Vitamin E's clinical biology has produced a famously mixed evidence base with some signal trials and many negative outcome trials. The HOPE trial (NEJM 2000) randomized 9,541 high-risk cardiovascular patients to α-tocopherol 400 IU/day vs. placebo for 4.5 years; no benefit on cardiovascular outcomes. The Women's Health Study (Lee 2005 JAMA) randomized 39,876 healthy women to α-tocopherol 600 IU every other day for 10 years; no benefit on CV events, no effect on total cancer, borderline reduction in CV mortality. The SELECT trial (Klein 2011 JAMA) randomized 35,533 men to α-tocopherol 400 IU/day, selenium 200 μg/day, both, or placebo for 7 years; the α-tocopherol arm showed a 17% increase in prostate cancer incidence vs. placebo at 5-7 years post-randomization. The Miller 2005 meta-analysis (Annals of Internal Medicine, PMID 15537682) of 19 RCTs (135,967 participants) examining high-dose vitamin E supplementation found a dose-dependent increase in all-cause mortality at doses ≥400 IU/day. These collectively argue strongly against prophylactic high-dose α-tocopherol supplementation in healthy adults.

Positive signals exist in specific contexts. The PIVENS trial (Sanyal 2010 NEJM) randomized 247 non-diabetic adults with biopsy-proven nonalcoholic steatohepatitis (NASH) to α-tocopherol 800 IU/day, pioglitazone, or placebo for 96 weeks; the vitamin E arm produced a 43% resolution-of-NASH rate vs. 19% placebo, a meaningful and clinically significant result that has shaped AASLD guidelines recommending vitamin E for biopsy-proven NASH in non-diabetic adults. The TEAM-AD trial (Dysken 2014 JAMA, PMID 24381967) randomized 613 patients with mild-to-moderate Alzheimer's disease to α-tocopherol 2,000 IU/day, memantine, combination, or placebo; the α-tocopherol arm showed slowed functional decline on ADCS-ADL by approximately 6.2 units over 2 years vs. placebo, suggesting a modest but real benefit. The pooled evidence supports alpha-tocopherol for slowing progression of mild-to-moderate AD at high doses, though the effect is modest and safety with anticoagulants requires attention. ATBC's 16% reduction in prostate cancer in Finnish male smokers on α-tocopherol 50 mg/daywas not confirmed in SELECT and is generally considered a chance finding.

Mixed tocopherols and tocotrienols have generated renewed interest. γ-tocopherol (the most abundant vitamin E isoform in the US food supply) has distinct antioxidant chemistry — it can trap peroxynitrite (RNOS) through its free 5-position, which α-tocopherol cannot — and there is epidemiologic and mechanistic work suggesting γ-tocopherol may have anti-inflammatory and anti-cancer effects (Campbell 2003; Jiang 2014). Tocotrienols, particularly δ- and γ-tocotrienols from palm oil and annatto, have been studied for effects on cholesterol synthesis (HMG-CoA reductase post-translational regulation), breast cancer cell biology in vitro, and osteoporosis — though human data are limited and mechanism-over-outcome-trial. Mixed tocopherol/tocotrienol supplements are popular in the biohacking and integrative medicine communities; evidence that they outperform isolated α-tocopherol for defined outcomes is limited.

BodyHackGuide's take: vitamin E is essential, but the sweet spot for adult supplementation in most populations is dietary adequacy (15 mg α-tocopherol equivalents per day, easily met by nuts, seeds, vegetable oils, whole grains, and leafy greens), rather than therapeutic supplementation. Exceptions with defined benefit: NASH in non-diabetic adults (800 IU/day under hepatology supervision), mild-to-moderate Alzheimer's (2,000 IU/day with attention to bleeding risk), and rare AVED or abetalipoproteinemia (specialist-directed mega-dose replacement). High-dose α-tocopherol supplementation in healthy populations has shown harm signals (SELECT prostate cancer, Miller meta-analysis all-cause mortality) and no convincing benefit for CV prevention. Vitamin E belongs in the fat-soluble family alongside vitamin A, vitamin D3, and vitamin K2; co-stacking requires attention to high-dose α-tocopherol blunting vitamin K-dependent carboxylation (the anticoagulant effect) and RXR heterodimer crosstalk affecting vitamin A / vitamin D signaling.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Vitamin E Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility